Effect of Intravitreal Aflibercept Injection on Microaneurysm in Patients with Diabetic Macular Edema - Effect of Intravitreal Aflibercept Injection

Department of Ophthalmology, Mie University0 个研究点目标入组 30 人开始时间: 2015年7月14日最近更新: 2023年10月17日

试验速览

暂无简介。

•1)Panretinal or macular laser photocoagulation (including grid photocoagulation) within 3 months 2)Macular ischemia involving the center of the macula that is likely to preclude improvement in BCVA 3)Vitreomacular traction evident biomicroscopically or on OCT 4)Active proliferative diabetic retinopathy (characterized by any of the following: vitreous hemorrhage, preretinal hemorrhage, disc neovascularization, retinal neovascularization, and proliferative membrane or tractional retinal detachment with neovascularization) 5)Glaucoma or optic atrophy 6)History of any vitreous surgery 7)Aphakia 8)Treatment with any drug injected into the vitreous cavity or around the eye within 3 months 9)Cataract that prevents fundus examinations required for the study 10)Cataract surgery within 3 months 11)Severe systemic conditions such as severe heart disease and cerebrovascular disorder 12)Significant renal impairment defined as a serum creatinine level of over 2.0 mg/dL or Stage 3B or greater overt nephropathy (including subjects requiring hemodialysis) 13)Uncontrolled hypertension (systolic over 180, diastolic over110 mmHg) 14)Uncontrolled diabetes mellitus (HbA1c over 10% [NGSP]) 15)Ocular inflammation including trace or above in the study eye 16)Pregnant or breast-feeding women.

发起方

Department of Ophthalmology, Mie University